Latest News
Harbour BioMed and Sinopharm establish innovation R&D consortium
27 July 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) declared on Monday that it has entered into a strategic collaboration with China National Pharmaceutical Group Co Ltd (Sinopharm) to establish the Sinopharm - Harbour BioMed Innova...
argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102
27 July 2026 - Immunology innovation company argenx (Euronext & Nasdaq: ARGX) disclosed on Monday that it has entered into a definitive agreement to acquire biopharmaceutical company Forte Biosciences Inc (Nasdaq: FBRX) for USD77 per share in cas...
AstraZeneca reports positive Phase III survival results for Sone-Ve in advanced gastric cancers
27 July 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III CLARITY-Gastric01 trial, with sonesitatug vedotin (Sone-Ve) delivering a statistically signif...
Tristel launches premium 3T Pro digital compliance platform
27 July 2026 - Infection prevention company Tristel plc (AIM: TSTL) announced on Monday that it has commercially launched 3T Pro, a premium tier of its 3T digital compliance platform, marking the first paid version of the platform as the company seek...
Faron reports encouraging first overall survival data from BEXMAB frontline HR-MDS trial
27 July 2026 - Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM: FARN) (First North: FARON) on Monday reported its first overall survival data from treatment-naïve higher-risk myelodysplastic syndrome patients enrolled in the Phase 1/2 B...